Vitiligo Management Guidelines

Initial Assessment and Treatment

• The British Journal of Dermatology recommends checking thyroid function in all patients with vitiligo due to the high prevalence of autoimmune thyroid disease in this population 1, 2
• Document disease extent with serial photographs every 2-3 months to objectively monitor treatment response 2
• In patients with trauma-induced vitiligo, assess for Koebner phenomenon to determine surgical candidacy 2

Treatment Algorithm by Disease Extent and Skin Type

• For limited/localized vitiligo, the British Journal of Dermatology suggests starting with potent or very potent topical corticosteroids, achieving 15-25% repigmentation in approximately 43% of patients 1, 2, 3
• Topical calcineurin inhibitors should be considered as first-line alternatives to corticosteroids, particularly for facial or eyelid involvement, providing comparable efficacy with a superior safety profile 1, 4, 3
• For widespread/generalized vitiligo, narrowband UVB phototherapy is the preferred treatment, offering superior efficacy and safety compared to PUVA 1, 5, 2

Surgical Options

• Surgical treatments should only be performed when disease has been completely stable for at least 12 months, with no new lesions, no Koebner phenomenon, and no extension of existing lesions 1, 5, 2
• Split-skin grafting provides superior cosmetic and repigmentation results compared to minigraft procedures 1, 5, 3

Treatments NOT Recommended

• Oral dexamethasone cannot be recommended due to unacceptable risk of side effects 1, 5
• Topical calcipotriol monotherapy has no effect and is not recommended 4
• Surgical treatments in children are not recommended due to lack of safety data 5

Depigmentation for Extensive Disease

• Depigmentation with monobenzyl ether of hydroquinone should be reserved only for adults with >50% depigmentation or extensive facial/hand involvement who cannot or choose not to seek repigmentation and can accept permanent inability to tan 1, 5

Critical Pitfalls to Avoid

• Never extend potent topical corticosteroid use beyond 2 months to prevent skin atrophy 1, 2
• Never perform surgery in patients with active Koebnerization or recent disease progression 2

Psychological Support

• Offer psychological interventions to improve coping mechanisms, as vitiligo can be particularly distressing and stigmatizing 5, 2, 3

Vitiligo Management Guidelines

First-Line Treatment Selection

• The British Association of Dermatologists recommends initiating treatment with potent or very potent topical corticosteroids, such as clobetasol propionate 0.05% or betamethasone valerate 0.1%, applied twice daily for a maximum of 2 months, achieving 15-25% repigmentation in approximately 43% of patients 6, 7
• Topical calcineurin inhibitors, such as pimecrolimus 1% or tacrolimus 0.1%, applied twice daily, provide comparable efficacy to clobetasol with a superior safety profile, and are particularly recommended for facial or eyelid involvement 6
• In children, calcineurin inhibitors should be strongly preferred over potent steroids due to a better short-term safety profile 6

Treatment Monitoring and Adjunctive Management

• The British Association of Dermatologists suggests documenting disease extent with serial photographs every 2-3 months using VASI or VETF scoring systems to objectively monitor response 7
• Cosmetic camouflage, including fake tanning products, improves quality of life, with a DLQI improvement from 7.3 to 5.9 7
• Sunscreens are essential as depigmented skin is more sensitive to sunburn, and psychological support is mandatory, with interventions to improve coping mechanisms, as vitiligo has a QoL impact comparable to psoriasis 7

Depigmentation for Extensive Disease

• Topical 4-methoxyphenol (4MP) produces total depigmentation in 69% of subjects within 4-12 months, and Q-switched ruby laser (QSRL) achieves total depigmentation in 69% within 7-14 days 6

Evidence‑Based Management of Vitiligo

Initial Assessment

• Baseline thyroid function testing is recommended for all patients because autoimmune thyroid disease is common in vitiligo. 8
• Document disease extent with standardized serial photographs every 2–3 months to objectively monitor response. 8

First‑Line Topical Therapy

Potent/Very Potent Corticosteroids

• Clobetasol propionate 0.05 % (or betamethasone valerate 0.1 %) applied twice daily for a maximum of 2 months is an initial treatment for stable vitiligo; extending beyond 2 months markedly increases the risk of skin atrophy. 8
• This regimen yields 15–25 % repigmentation in approximately 43 % of treated individuals. 8

Topical Calcineurin Inhibitors

• Tacrolimus 0.1 % or pimecrolimus 1 % applied twice daily provides efficacy comparable to potent steroids with a superior safety profile, making it the preferred option for facial or eyelid involvement and for children. [8][9]

Phototherapy for Widespread Disease

• Narrowband UVB (NB‑UVB) is superior to PUVA in both efficacy and safety for generalized vitiligo and should be considered when topical agents are insufficient or disease impact on quality of life is substantial. [8][9]
• NB‑UVB is especially advantageous for patients with darker skin types (IV–VI), where repigmentation is more readily apparent. [8][9]
• Safety limit: up to 200 NB‑UVB treatment sessions for skin types I–III; no defined upper limit for types IV–VI. 8

Surgical Considerations (Stable Disease)

• Surgery is only appropriate when disease has been completely stable for ≥12 months with no new lesions, no Koebner phenomenon, and no extension of existing lesions. 8
• Split‑skin grafting offers superior cosmetic outcomes and repigmentation compared with minigraft techniques. 8
• Autologous epidermal cell suspension applied to laser‑abraded lesions, followed by NB‑UVB or PUVA, is considered the optimal surgical adjunct. 8

Systemic Therapy

• Oral dexamethasone is not recommended for vitiligo because the risk of adverse effects outweighs any potential benefit in halting disease progression. 8

Depigmentation for Extensive Disease

• Monobenzyl ether of hydroquinone (MBEH) depigmentation therapy should be reserved for patients with >50 % body surface depigmentation or extensive facial/hand involvement who elect not to pursue repigmentation and accept permanent loss of tanning ability. [8][9]

Supportive Care

• Daily broad‑spectrum sunscreen use is advised for all patients to protect depigmented skin from sunburn and photodamage. [8][9]
• Psychological counseling and support improve coping, as vitiligo’s impact on quality of life is comparable to that of psoriasis. Parents of children with vitiligo should also be offered counseling. [8][9]

Monitoring and Follow‑Up

• Serial standardized photographs every 2–3 months should be used to assess treatment response. [8][9]
• If no clinical improvement is observed after 2 months of topical therapy, the treatment plan should be reassessed. [8][9]
• Patients who fail topical therapy should be referred for phototherapy (NB‑UVB or PUVA). 9